Clinical trial NCT05656833: Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma
Official title: Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Melasma
Keywords: Facial Melasma
Cyspera
Clear & Brilliant Laser
Laser
Melasma
Lead sponsor: UnionDerm
Sponsor class: OTHER
Collaborators: name: Solta Medical
name: Skin of Color Society
name: Scientis
First posted: 2022-12-19
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Single Center, Prospective, With Before-After Analysis
Primary purpose: TREATMENT

Brief summary: The primary objective of our study is to determine the efficacy of combined topical cysteamine cream with a 1927 diode non-ablative laser (Clear + Brilliant Permea®; Solta Medical, Inc.), compared to topical cysteamine (Cyspera) alone in the treatment of melasma.

The main questions it aims to answer are

* If melasma treatment with topical cysteamine cream is more effective when used with the Clear \& Brilliant® Permea laser
* The safety \& efficacy of melasma treatment in various skin types using the Clear \& Brilliantt® Permea laser in combination with topical cysteamine.

Participants will

* Come into our office for an initial screening appointment to determine if participant is eligible for the study
* Come in for 3 laser treatments, 4 weeks apart, on 1 side of the face
* Use the study provided Cyspera topical cream every day on the entire face for the 12 weeks on the study.

Researchers will compare the side of the participants face not treated with laser to the side of the face treated with laser. The participants will be using Cyspera on both sides of their face.


Eligibility criteria: Inclusion Criteria:

* Healthy subjects of Skin Type I-VI females.
* Subjects must be between 18 and 74 years of age, and must have visible melasma on the face.
* Subjects must read, understand, and sign the Informed Consent.
* Subjects must be willing and able to comply with all follow-up requirements.

Exclusion Criteria:

* Subjects must not have active or localized or systemic infections.
* Subjects must not be immunocompromised.
* Subjects must not have a coagulation disorder, and must not be using anticoagulation -medications.
* Subjects must not have history of surgical or cosmetic treatment, including prior skin lightening agents, microneedling or microdermabrasion, or laser or light-based therapies, to the planned treatment areas in the prior 8 weeks.
* Subjects must not have photosensitivity or allergy.
* Subjects must not be mentally incompetent.
* Subjects must not be pregnant or breastfeeding.
* History of skin cancer or pre-cancerous lesions in the treatment area
* Subjects must not be currently using aspirin or antioxidants.
* Subjects must not refuse to sign the Informed Consent document and/or refuse to comply with all follow-up requirements.
* Subjects must never have had gold therapy.
* Subjects must never have had radiation therapy to the face. Recent or current suntan or sunburn within 2 weeks.
* Clinically dysplastic nevi in the treatment area.
* Subjects must not have had collagen, other methods of tissue augmentation, botox, chemical peels, dermabrasion, or resurfacing within the last year.
* Oral retinoid (Accutane or Soriatane) or photosensitizing drugs, e.g. Declomycin®, a tetracycline with light absorption in the range of 400 to 450 nm use within 24 months of study entry.
* Topical retinoid therapy on face within one month of study entry.
* History of keloids or hypertrophic scars
* A history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, or photodermatosis.

Primary outcomes:
measure: The primary objective of our study is to determine the efficacy of combined topical cysteamine cream with a 1927 diode non-ablative laser (Clear + Brilliant Permea®; Solta Medical, Inc.), compared to topical cysteamine alone in the treatment of melasma.
timeFrame: 12 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: UnionDerm
state: New York
Study officials:
References: